Anika Therapeutics (ANIK) Revenue Growth (3y) (2013 - 2026)
Anika Therapeutics (ANIK) Revenue Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.69 Bn | 87.82 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.92 Bn | 32.18 Bn | 1.97 Bn | 2.84% |
| 3 | Zoetis | 32.57 Bn | 30.63 Bn | 1.62 Bn | 4.19% |
| 4 | Takeda Pharmaceutical | 27.52 Bn | 23.46 Bn | 4.39 Bn | -4.46% |
| 5 | United Therapeutics | 23.08 Bn | 20.93 Bn | 648.10 Mn | 15.52% |
| 6 | RedHill Biopharma | 22.43 Bn | 22.43 Bn | - | - |
| 7 | Viatris | 20.23 Bn | 18.42 Bn | 1.16 Bn | -2.00% |
| 8 | Neurocrine Biosciences | 17.78 Bn | 16.46 Bn | 800.70 Mn | 24.66% |
| 9 | Elanco Animal Health | 12.61 Bn | 12.18 Bn | 785.00 Mn | 2.94% |
| 10 | Anika Therapeutics | 204.05 Mn | 137.26 Mn | 19.00 Mn | -7.92% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.92% |
| Dec 31, 2025 | 135.04% |
| Sep 30, 2025 | -11.60% |
| Jun 30, 2025 | -10.72% |
| Mar 31, 2025 | -10.66% |
| Dec 31, 2024 | -5.11% |
| Sep 30, 2024 | -9.24% |
| Jun 30, 2024 | -6.96% |
| Mar 31, 2024 | -5.41% |
| Dec 31, 2023 | -27.83% |
| Sep 30, 2023 | 9.37% |
| Jun 30, 2023 | 13.03% |
| Mar 31, 2023 | 2.33% |
| Dec 31, 2022 | -27.93% |
| Sep 30, 2022 | 10.68% |
| Jun 30, 2022 | 9.24% |
| Mar 31, 2022 | 14.07% |
| Dec 31, 2021 | 9.94% |
| Sep 30, 2021 | 13.86% |
| Jun 30, 2021 | 7.68% |